What alternative systemic therapy can be used for hepatocellular carcinoma in a patient with impaired renal function (creatinine clearance ~22 mL/min) who cannot receive lenvatinib?

Alternative Systemic Therapy for HCC with Severe Renal Impairment

For a patient with hepatocellular carcinoma and creatinine clearance of 22.71 mL/min (severe renal impairment) who cannot receive lenvatinib, atezolizumab plus bevacizumab should be offered as first-line therapy if the patient has preserved liver function (Child-Pugh A) and good performance status (ECOG 0-1), provided there are no contraindications to bevacizumab or atezolizumab. 1

Why Lenvatinib Cannot Be Used

The FDA label explicitly states: "There is no recommended dose of LENVIMA for patients with HCC and severe renal impairment" (CrCl 15-29 mL/min). 1 Your patient's creatinine clearance of 22.71 mL/min falls squarely in this contraindicated range for HCC treatment.

First-Line Alternative: Atezolizumab + Bevacizumab

This combination is the preferred first-line option based on multiple guidelines:

• The 2022 AGA guidelines recommend atezolizumab + bevacizumab over sorafenib for patients with preserved liver function not eligible for locoregional therapy 2
• The 2024 ASCO guidelines state this combination "may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, ECOG PS 0-1" 3, 4
• The 2025 EASL guidelines designate this as "first-choice standard of care" 5

Critical safety requirement: The patient must undergo endoscopic evaluation and treatment for esophageal varices before starting bevacizumab due to bleeding risk. 2, 6

Contraindications to assess:

• Prior autoimmune diseases
• Allogeneic stem cell or solid organ transplantation
• Idiopathic pulmonary fibrosis or pneumonitis
• Co-infection with hepatitis B and C viruses
• Portal hypertension with untreated varices 2

Second-Line Alternative: Sorafenib

If atezolizumab + bevacizumab is contraindicated, sorafenib is the appropriate alternative for patients with severe renal impairment:

• Unlike lenvatinib, sorafenib has no specific renal dose restrictions for HCC patients in the FDA labeling
• The 2022 AGA guidelines recommend "either lenvatinib or sorafenib over no systemic therapy" as alternatives when atezolizumab + bevacizumab cannot be used 2
• The 2020 ASCO guidelines support sorafenib as first-line therapy "where there are contraindications to atezolizumab and/or bevacizumab" 3

Sorafenib dosing: 400 mg orally twice daily 2

Key consideration: Patients who value blood pressure control over adverse skin reactions may prefer sorafenib. 2

Treatment Algorithm for This Patient

1. Assess liver function: Confirm Child-Pugh A status (required for all systemic therapies)
2. Assess performance status: Confirm ECOG 0-1
3. Screen for atezolizumab + bevacizumab contraindications:
   • Perform upper GI endoscopy to evaluate and treat varices
   • Review autoimmune history
   • Check for prior transplantation
   • Assess for pulmonary fibrosis/pneumonitis
4. If no contraindications exist: Offer atezolizumab 1200 mg IV + bevacizumab 15 mg/kg IV every 3 weeks 2
5. If contraindications exist: Offer sorafenib 400 mg PO twice daily 2

Important Caveats

Do not use:

• Lenvatinib (explicitly contraindicated with CrCl 22.71 mL/min for HCC) 1
• Durvalumab + tremelimumab (while effective, atezolizumab + bevacizumab showed superior overall survival in head-to-head comparison) 5

Renal monitoring: Severe renal impairment increases lenvatinib concentrations in other cancer types (DTC, RCC, endometrial carcinoma), which is why it's contraindicated in HCC with severe renal dysfunction. 1 This patient requires close monitoring of renal function regardless of chosen therapy.

Portal vein invasion: If present, ensure this is documented as lenvatinib was not studied in patients with main portal vein invasion, though this is less relevant given the renal contraindication. 2